Revista de Hematología

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista de Hematología >Year 2013, Issue 4

Da Costa O, Borrego M, Gil M, López J
Course of pregnancy in chronic myelogenous leukemia patients given tyrosien kinase inhibitors
Rev Hematol Mex 2013; 14 (4)

Language: Español
References: 9
Page: 178-181
PDF: 309.62 Kb.

Full text


Background: Tyrosine kinase Inhibitors (TKIs), constitute the treatment of choice of the CML, since that they achieve a higher response rate and have improved the life expectancy of this disease. Many female patients, are in reproductive age, in them it is recommended the use of contraceptive methods since to Imatinib demonstrated teratogenicity in animals and to the unknown safety profile of an inadvertent exposure during the embryogenesis to Nilotinib or Dasatinib. We described the pregnancy evolution, delivery and characteristics of the product of patients with CML diagnosis who have procreated on a planned or inadvertent way during the treatment with TKIs, who assist to consultation in the BMS (Caracas-Venezuela). All Medical reports of female gender treated with TKIs were reviewed by diagnose of CML in the BMS, and 9 females became pregnant during or after the TKI treatment. Six patients were in chronic phase, 2 in accelerated phase and 1 in blast crisis. Only 2 patients were in MMR at the moment of pregnancy. Five patients were receiving treatment with Imatinib, 1 with Nilotinib and 1 with Dasatinib. Only 2 patients were suspended the TKI treatment previous to the gestation (planned pregnancy). All patients who were not in CP, presented complications that required hospitalization. Every product has good health except the twins that lost their control visits.
Discussion and conclusion. . Any product presented congenital malformation The patients with CML in chronic phase, well controlled with MMR at the pregnancy moment, had then good evolution, but those who were not in MMR, progressed in the postpartum period to blast crisis with fatal outcome. It is not recommended the use of TKIs during the conception period or in embryogenesis phase.

Key words: Chronic Myeloid Leukemia: CML, Mayor Molecular Response: MMR, Chronica Phase: CP, Acelerate phase: AP, Blastic Crisis: BC, Pregnancy.


  1. Baccarani M, Cortes J, Panel F, et al. Chronic myeloid leukemia: an update of concepts and managment recomendations of European LeukemiaNet: an update of concepts and management recommendations of European LuekemiaNet. J Clin 2009;27:604-605.

  2. Pye S, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008;111:5505-5508.

  3. Ault P, Kantarjian H, O Brien S. Pregnancy among Patients with Chronic Mieloid Leukaemia. J Clin Oncol 2008;24:1204- 1208.

  4. Zhonghua Xue Ye Xue Za Zhi. Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;33:6-9.

  5. Hensley M, Ford JM. Imatinib Treatment: Specific Issues Related to Safety. Fertility and Pregnancy Semin Hematol 2003;40(Suppl 2):21-25.

  6. Seonaid MP, Cortes J, Ault P. The Effects of Imatinib on Pregnancy Outcome. Blood 2008;111:5505-5509.

  7. Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley J, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia 2013. Blood 2013;122:872-884.

  8. Kuwuabara A, Babb A, et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 2011;116:1014-1016.

  9. Pavlovsky C, Giere I, Van Thillo G. Hindawi Publishing Corporation. Case Reports in Hematology 2012, Article ID 624590, 4 pag.

>Journals >Revista de Hematología >Year 2013, Issue 4

· Journal Index 
· Links 

Copyright 2019